Drugs / Individual Patient TCR-Transduced PBL
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06904066 | Oct 2026 → Apr 2029 expected | acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04536922 | Jan 2021 | anal squamous cell carcinoma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 2 | NCT03412877 | Sep 2018 → Mar 2028 expected | breast cancer, neuroendocrine neoplasm, non-small cell lung carcinoma, ovarian cancer +1 | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04135092 | — | — | National Institutes of Health Clinical Center (CC) | No longer available | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Individual Patient TCR Transduced PBL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04135092 ↗ |
| Action | Deplete | “The neoantigen TCR gene-modified cells can recognize and destroy the autologous cancer in vitro.” NCT03412877 ↗ |
| Modality | Cell therapy | “The gene transfer therapy is the return of those white blood cells back to the person.” NCT03412877 ↗ |
| Route | Intravenous | “Cells will be infused intravenously on the Patient Care Unit” NCT03412877 ↗ |
| Target | TP53 | “recognize the mutated TP53 shared oncogene” NCT04135092 ↗ |